With "fivefold increase in half-life" and "no safety complications whatsoever," CSL Behring's long-acting fusion protein that links recombinant coagulation factor IX with recombinant albumin (rIX-FP) "is going to benefit patients in an extraordinary way," Debra Kennedy, head of coagulant and oncology therapeutics, told BioWorld Today.